Optipharm (153710) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Optipharm (153710) reported revenue of 22.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202522.3 billion KRW-2.4 billion KRW-2.5 billion KRW[source]
202419.6 billion KRW-2.5 billion KRW-2.4 billion KRW[source]
202317.4 billion KRW-2.6 billion KRW-2.4 billion KRW[source]
202216.0 billion KRW-3.4 billion KRW-2.0 billion KRW[source]
202114.3 billion KRW-4.5 billion KRW-3.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202540.8 billion KRW15.4 billion KRW25.4 billion KRW[source]
202443.3 billion KRW16.0 billion KRW27.3 billion KRW[source]
202339.3 billion KRW14.1 billion KRW25.1 billion KRW[source]
202241.2 billion KRW12.2 billion KRW29.0 billion KRW[source]
202141.2 billion KRW10.2 billion KRW31.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice